(Q35896291)

11 August 2017

1 reference

title

Calculation of quality adjusted life years in the published literature: a review of methodology and transparency (English)

1 reference

11 August 2017

Gerald Richardson

1

1 reference

PubMed ID

15386669

11 August 2017

Andrea Manca

series ordinal

2

1 reference

PubMed ID

15386669

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

11 August 2017

1 reference

11 August 2017

13

1 reference

11 August 2017

1203-1210

1 reference

11 August 2017

12

1 reference

Understanding controlled trials: baseline imbalance in randomised controlled trials

11 August 2017

1 reference

A randomised comparison and economic evaluation of laparoscopic-assisted hysterectomy and abdominal hysterectomy.

21 January 2018

1 reference

Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods

21 January 2018

1 reference

7 January 2021

Analysis of serial measurements in medical research

1 reference

7 January 2021

Effect of regression to the mean on decision making in health care

1 reference

7 January 2021

Missing... presumed at random: cost-analysis of incomplete data

1 reference

7 January 2021

Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens

1 reference

7 January 2021

Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients

1 reference

7 January 2021

Cost-utility analysis of the cochlear implant in children.

1 reference

7 January 2021

Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services.

1 reference

7 January 2021

Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial

1 reference

7 January 2021

A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results

1 reference

7 January 2021

Cost-utility analysis of open versus laparoscopic groin hernia repair: results from a multicentre randomized clinical trial

1 reference

7 January 2021

A UK trial-based cost--utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris

1 reference

7 January 2021

Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.

1 reference

7 January 2021

Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial.

1 reference

7 January 2021

Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction

1 reference

7 January 2021

The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies

1 reference

7 January 2021

The death of cost-minimization analysis?

1 reference

7 January 2021

Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.

1 reference

7 January 2021

Technology assessment of the Dutch Lung Transplantation Program.

1 reference

7 January 2021

Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis

1 reference

7 January 2021

Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis.

1 reference

7 January 2021

Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial

1 reference

7 January 2021

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

1 reference

7 January 2021

Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial

1 reference

7 January 2021

Cost-effectiveness of preventive occupational therapy for independent-living older adults.

1 reference

7 January 2021

Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEC.901

1 reference

11 August 2017

1 reference

PubMed ID

15386669